Contact Congress about S. 3019: No Big Blockbuster Bailouts Act

Some rare-disease drugs would get extra time before Medicare can put them into drug price talks. The bill doubles the spending cutoff for orphan-only drugs from $200 million to $400 million. It would start applying to price years that begin on or after January 1, 2028.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

No Big Blockbuster Bailouts Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 3019: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects people tied most closely to rare-disease drugs. Drug companies that sell orphan-only drugs could get more time before Medicare price talks begin. Medicare officials would have to use a different spending cutoff for that small group of drugs. Patients with rare diseases could be affected if the change alters which drugs face negotiation and when, although the bill does not spell out the effect on their own costs.

Why this matters: This bill matters because it could delay Medicare price talks for some very expensive rare-disease drugs. That could change when Medicare starts seeking lower prices on those medicines. Supporters may see that as a way to protect research and development for small patient groups. Critics may see it as a delay in savings for Medicare and taxpayers. The bill itself does not say how large those effects would be.

Key provisions in S. 3019

• This bill changes part of the Social Security Act that tells Medicare how to choose drugs for price negotiation. It updates the rules for the Medicare Drug Price Negotiation Program.
• It applies only to orphan drugs, which are drugs meant for rare diseases. The drug must be approved only for one or more rare diseases or conditions under the federal food and drug law.
• For those orphan-only drugs, Medicare would use a higher spending cutoff. The bill raises that number from $200 million to $400 million.
• This higher cutoff affects one step in deciding whether a drug becomes a selected drug for negotiation. That step looks at how much Medicare spends on the drug.
• The new rule would not start right away. It would first apply to initial price applicability years that begin on or after January 1, 2028.

How Modern Action helps you take action on S. 3019

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 3019

What is S. 3019?

Some rare-disease drugs would get extra time before Medicare can put them into drug price talks. The bill doubles the spending cutoff for orphan-only drugs from $200 million to $400 million. It would start applying to price years that begin on or after January 1, 2028.

How do I support or oppose S. 3019?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 3019?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 3019?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.